Disposition of firocoxib in late pregnant and early postpartum mares

J Vet Pharmacol Ther. 2016 Apr;39(2):196-8. doi: 10.1111/jvp.12253. Epub 2015 Jul 23.

Abstract

Pregnancy induces several physiologic changes that might impact the bioavailability, distribution, metabolism, and excretion of drugs. The objective of this study was to determine the effects of pregnancy on the disposition of oral firocoxib in mares. Seven pony mares received oral firocoxib paste at a dose of 0.1 mg/kg during late pregnancy and again 12 to 33 days postpartum. Firocoxib concentrations were measured in plasma by HPLC with ultraviolet detection. Maximum plasma concentrations were significantly lower in pregnant (50.0 ± 21.8 ng/mL) than in postpartum (73.7 ± 25.6 ng/mL) mares. Plasma concentrations 24 h after administration, time to maximum plasma concentrations, and area under the plasma concentration versus time curve were not significantly different between late pregnancy and the postpartum period in mares.

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • 4-Butyrolactone / analogs & derivatives*
  • 4-Butyrolactone / pharmacokinetics
  • Animals
  • Area Under Curve
  • Cyclooxygenase 2 Inhibitors / pharmacokinetics*
  • Female
  • Horses / metabolism*
  • Postpartum Period / metabolism*
  • Pregnancy
  • Pregnancy, Animal*
  • Sulfones / pharmacokinetics*
  • Tissue Distribution

Substances

  • Cyclooxygenase 2 Inhibitors
  • Sulfones
  • 4-Butyrolactone
  • firocoxib